Histanaz Tablet
NDC Package 29978-129-10

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Histanaz (pseudoephedrine hcl, pyrilamine maleate) tablets is uses Temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies: nasal congestionrunny noseitchy watery eyesitching of the nose and throat. This formulation utilizes a tablet delivery system. Marketed by Capital Pharmaceutical, Llc, this product is identified by NDC 29978-129 and is authorized under FDA application M012.

Identification & Billing

NDC Package Code
29978-129-10
Package Description
100 TABLET in 1 BOTTLE
Product Code
29978-129
11-Digit Billing Format
29978012910
RxNorm Crosswalk
  • RxCUI: 2727351 - pseudoephedrine HCl 60 MG / pyrilamine maleate 30 MG Oral Tablet
  • RxCUI: 2727351 - pseudoephedrine hydrochloride 60 MG / pyrilamine maleate 30 MG Oral Tablet

Clinical Specifications

Proprietary Name
Histanaz
Non-Proprietary Name
Pseudoephedrine Hcl, Pyrilamine Maleate
Substance Name
Pseudoephedrine Hydrochloride; Pyrilamine Maleate
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Pharmacologic Class
Usage Information
Uses Temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies: nasal congestionrunny noseitchy watery eyesitching of the nose and throat

Regulatory & Marketing

Labeler Name
Capital Pharmaceutical, Llc
Product Type
Human Otc Drug
FDA Application #
M012
Marketing Category
OTC MONOGRAPH DRUG -
Start Marketing Date
09-08-2025
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 29978-129-10 identifies a specific commercial package of 100 tablet in 1 bottle of Histanaz, a human over the counter drug labeled by Capital Pharmaceutical, Llc. This tablet is formulated for oral use and contains pseudoephedrine hydrochloride; pyrilamine maleate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Capital Pharmaceutical, Llc on September 08, 2025. The current certification is valid through December 31, 2027.

How is this Capital Pharmaceutical, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 29978012910. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
29978-129-10
11-Digit CMS (5-4-2)
29978-0129-10

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.